Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Blümner

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Arzneimittel-Forschung|September 1, 1987
[Plasma level and action of sotalol-HCL on the ECG interval after parenteral administration in healthy subjects]K D Rehm, K Schnelle, C J Dyde, et al.
Kidney International|March 1, 1988
Cell rubidium uptake: a method for studying functional heterogeneity in the nephronF X Beck, A Dörge, E Blümner, et al.
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension|December 1, 1989
Hypertension and micro-albuminuria in diabetic patients taking indapamideH U Janka, T Weitz, E Blümner, et al.
Clinical and Experimental Rheumatology|October 31, 2015
Combination of B cell biomarkers as independent predictors of response in patients with rheumatoid arthritis treated with rituximabH-P Tony, P Roll, H E Mei, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|January 1, 1996
Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO studyH Przuntek, D Welzel, M Gerlach, et al.
European Journal of Clinical Pharmacology|January 1, 1992
Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinuedH Przuntek, D Welzel, E Blümner, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Arzneimittel-Forschung|September 1, 1987
[Plasma level and action of sotalol-HCL on the ECG interval after parenteral administration in healthy subjects]K D Rehm, K Schnelle, C J Dyde, et al.
Kidney International|March 1, 1988
Cell rubidium uptake: a method for studying functional heterogeneity in the nephronF X Beck, A Dörge, E Blümner, et al.
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension|December 1, 1989
Hypertension and micro-albuminuria in diabetic patients taking indapamideH U Janka, T Weitz, E Blümner, et al.
Clinical and Experimental Rheumatology|October 31, 2015
Combination of B cell biomarkers as independent predictors of response in patients with rheumatoid arthritis treated with rituximabH-P Tony, P Roll, H E Mei, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|January 1, 1996
Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO studyH Przuntek, D Welzel, M Gerlach, et al.
European Journal of Clinical Pharmacology|January 1, 1992
Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinuedH Przuntek, D Welzel, E Blümner, et al.
Pageof 1